Division of Infectious Diseases, School of Medicine, Washington University in St. Louis, Saint Louis, Missouri, United States of America.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
PLoS Med. 2022 Mar 22;19(3):e1003959. doi: 10.1371/journal.pmed.1003959. eCollection 2022 Mar.
BACKGROUND: Global HIV treatment programs have sought to lengthen the interval between clinical encounters for people living with HIV (PLWH) who are established on antiretroviral treatment (ART) to reduce the burden of seeking care and to decongest health facilities. The overall effect of reduced visit frequency on HIV treatment outcomes is however unknown. We conducted a systematic review and meta-analysis to evaluate the effect of implementation strategies that reduce the frequency of clinical appointments and ART refills for PLWH established on ART. METHODS AND FINDINGS: We searched databases between 1 January 2010 and 9 November 2021 to identify randomized controlled trials (RCTs) and observational studies that compared reduced (6- to 12-monthly) clinical consultation or ART refill appointment frequency to 3- to 6-monthly appointments for patients established on ART. We assessed methodological quality and real-world relevance, and used Mantel-Haenszel methods to generate pooled risk ratios (RRs) with 95% confidence intervals for retention, viral suppression, and mortality. We evaluated heterogeneity quantitatively and qualitatively, and overall evidence certainty using GRADE. Searches yielded 3,955 records, resulting in 10 studies (6 RCTs, 3 observational studies, and 1 study contributing observational and RCT data) representing 15 intervention arms with 33,599 adults (≥16 years) in 8 sub-Saharan African countries. Reduced frequency clinical consultations occurred at health facilities, while reduced frequency ART refills were delivered through facility or community pharmacies and adherence groups. Studies were highly pragmatic, except for some study settings and resources used in RCTs. Among studies comparing reduced clinical consultation frequency (6- or 12-monthly) to 3-monthly consultations, there appeared to be no difference in retention (RR 1.01, 95% CI 0.97-1.04, p = 0.682, 8 studies, low certainty), and this finding was consistent across 6- and 12-monthly consultation intervals and delivery strategies. Viral suppression effect estimates were markedly influenced by under-ascertainment of viral load outcomes in intervention arms, resulting in inconclusive evidence. There was similarly insufficient evidence to draw conclusions on mortality (RR 1.12, 95% CI 0.75-1.66, p = 0.592, 6 studies, very low certainty). For ART refill frequency, there appeared to be little to no difference in retention (RR 1.01, 95% CI 0.98-1.06, p = 0.473, 4 RCTs, moderate certainty) or mortality (RR 1.45, 95% CI 0.63-3.35, p = 0.382, 4 RCTs, low certainty) between 6-monthly and 3-monthly visits. Similar to the analysis for clinical consultations, although viral suppression appeared to be better in 3-monthly arms, effect estimates were markedly influence by under-ascertainment of viral load outcomes in intervention arms, resulting in overall inclusive evidence. This systematic review was limited by the small number of studies available to compare 12- versus 6-monthly clinical consultations, insufficient data to compare implementation strategies, and lack of evidence for children, key populations, and low- and middle-income countries outside of sub-Saharan Africa. CONCLUSIONS: Based on this synthesis, extending clinical consultation intervals to 6 or 12 months and ART dispensing intervals to 6 months appears to result in similar retention to 3-month intervals, with less robust conclusions for viral suppression and mortality. Future research should ensure complete viral load outcome ascertainment, as well as explore mechanisms of effect, outcomes in other populations, and optimum delivery and monitoring strategies to ensure widespread applicability of reduced frequency visits across settings.
背景:全球艾滋病毒治疗方案一直致力于延长接受抗逆转录病毒治疗 (ART) 的艾滋病毒感染者 (PLWH) 的临床随访间隔,以减少寻求护理的负担并减轻卫生设施的负担。然而,减少就诊频率对艾滋病毒治疗结果的总体影响尚不清楚。我们进行了一项系统评价和荟萃分析,以评估减少接受 ART 的 PLWH 的临床预约和 ART 续药频率的实施策略的效果。
方法和发现:我们从 2010 年 1 月 1 日至 2021 年 11 月 9 日搜索数据库,以确定比较减少(6 至 12 个月)临床咨询或 ART 续药预约频率与 3 至 6 个月预约的随机对照试验 (RCT) 和观察性研究对于接受 ART 的患者。我们评估了方法学质量和现实相关性,并使用 Mantel-Haenszel 方法生成保留、病毒抑制和死亡率的汇总风险比 (RR),置信区间为 95%。我们使用 GRADE 定量和定性评估异质性和总体证据确定性。搜索产生了 3955 条记录,最终纳入了 10 项研究(6 项 RCTs、3 项观察性研究和 1 项研究同时提供观察性和 RCT 数据),涉及 15 个干预臂,共有来自 8 个撒哈拉以南非洲国家的 33599 名成年人(≥16 岁)。减少的就诊频率发生在卫生机构,而减少的 ART 续药则通过医疗机构或社区药房和依从性小组提供。除了一些 RCT 研究环境和资源外,这些研究都非常务实。在比较减少临床咨询频率(6 或 12 个月)与 3 个月咨询的研究中,保留率似乎没有差异(RR 1.01,95%CI 0.97-1.04,p=0.682,8 项研究,低确定性),并且这种发现在 6 个月和 12 个月的咨询间隔和交付策略中是一致的。病毒抑制效果估计受到干预臂中病毒载量结果确定不足的极大影响,导致证据不确定。同样,关于死亡率(RR 1.12,95%CI 0.75-1.66,p=0.592,6 项研究,极低确定性)也没有足够的证据得出结论。对于 ART 续药频率,保留率(RR 1.01,95%CI 0.98-1.06,p=0.473,4 项 RCT,中等确定性)或死亡率(RR 1.45,95%CI 0.63-3.35,p=0.382,4 项 RCT,低确定性)在 6 个月和 3 个月就诊之间似乎差异不大。与临床咨询分析相似,尽管 3 个月就诊手臂的病毒抑制似乎更好,但效果估计受到干预臂中病毒载量结果确定不足的极大影响,导致总体证据不一致。本系统评价受到可用研究数量的限制,无法比较 12 个月与 6 个月的临床咨询,缺乏比较实施策略的数据,并且缺乏来自撒哈拉以南非洲以外的中低收入国家的儿童、重点人群和证据。
结论:基于这项综合研究,将临床咨询间隔延长至 6 或 12 个月,将 ART 配药间隔延长至 6 个月,似乎与 3 个月间隔的保留率相似,对病毒抑制和死亡率的结论则不太可靠。未来的研究应确保完全确定病毒载量结果,并探索作用机制、其他人群的结果以及最佳的交付和监测策略,以确保在各种环境中广泛应用减少就诊频率。
Cochrane Database Syst Rev. 2022-2-1
Cochrane Database Syst Rev. 2019-6-17
Cochrane Database Syst Rev. 2017-5-25
Cochrane Database Syst Rev. 2021-4-29
Glob Health Sci Pract. 2021-6-30
J Acquir Immune Defic Syndr. 2021-6-1